{
  "symbol": "KRYS",
  "company_name": "Krystal Biotech Inc",
  "ir_website": "https://ir.krystalbio.com/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "Krystal Biotech to Present at Upcoming Investor Conferences",
          "url": "https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-present-upcoming-investor-conferences-1",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Krystal Biotech, Inc.](/sites/g/files/knoqqb89436/themes/site/nir_pid1356/dist/images/KRYS-logo-black.svg) ](https://www.krystalbio.com/)\n\n# Investors \n\nInvestor Relations \n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News Releases](/news-releases)\n  * [Events](/events-and-presentations/events)\n  * [Stock Information](/stock-information/stock-quote-chart)\n  * [SEC Filings](/financial-information/sec-filings)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n  * [Scientific Publications](/select-scientific-publications)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Investor FAQs](/shareholder-services/investor-faqs)\n\n\n\n## \n\nKrystal Biotech to Present at Upcoming Investor Conferences\n\nNovember 27, 2024 \n\n[Download PDF](/node/10426/pdf)\n\nPITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc](https://www.krystalbio.com/). (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:\n\n  * Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET\n  * 7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:10 pm ET\n\n\n\nEach presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s [website](https://ir.krystalbio.com/events-and-presentations/events). Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.\n\n**About Krystal Biotech, Inc.**\n\nKrystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit [http://www.krystalbio.com](http://www.krystalbio.com/), and follow @KrystalBiotech on [LinkedIn](https://www.linkedin.com/company/krystal-biotech-inc/) and [X](https://twitter.com/KrystalBiotech) (formerly Twitter).\n\n**CONTACT****Investors and Media:** Stéphane PaquetteKrystal Biotechspaquette@krystalbio.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI4OTgxMyM2NTkzNDI1IzIwOTE5Nzk=)![](https://ml.globenewswire.com/media/YWY3ODhkYmItZjJjYi00ZjFjLTgxODMtYmUzNDViYmM2YWNkLTExMDM1NTA=/tiny/Krystal-Biotech-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68/small/krys-logo-no-background-with-registered-symbol-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68)\n\nSource: Krystal Biotech, Inc.\n"
        },
        {
          "title": "Krystal Biotech to Present at Stifel 2024 Healthcare Conference",
          "url": "https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-present-stifel-2024-healthcare-conference",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Krystal Biotech, Inc.](/sites/g/files/knoqqb89436/themes/site/nir_pid1356/dist/images/KRYS-logo-black.svg) ](https://www.krystalbio.com/)\n\n# Investors \n\nInvestor Relations \n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News Releases](/news-releases)\n  * [Events](/events-and-presentations/events)\n  * [Stock Information](/stock-information/stock-quote-chart)\n  * [SEC Filings](/financial-information/sec-filings)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n  * [Scientific Publications](/select-scientific-publications)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Investor FAQs](/shareholder-services/investor-faqs)\n\n\n\n## \n\nKrystal Biotech to Present at Stifel 2024 Healthcare Conference\n\nNovember 12, 2024 \n\n[Download PDF](/node/10401/pdf)\n\nPITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc](https://www.krystalbio.com/). (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:55 am ET and host investor meetings throughout the day.\n\nA webcast of the presentation will be available [here](https://wsw.com/webcast/stifel96/krys/2142662) beginning at 10:55 am ET on Monday, November 18, 2024 and will be posted on the Investors section of the Company’s [website](https://ir.krystalbio.com/events-and-presentations/events).\n\n**About Krystal Biotech, Inc.**\n\nKrystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit [http://www.krystalbio.com](http://www.krystalbio.com/), and follow @KrystalBiotech on [LinkedIn](https://www.linkedin.com/company/krystal-biotech-inc/) and [X](https://twitter.com/KrystalBiotech) (formerly Twitter).\n\n**CONTACT****Investors and Media:** Stéphane PaquetteKrystal Biotechspaquette@krystalbio.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MTUwMiM2NTc2NDYxIzIwOTE5Nzk=)![](https://ml.globenewswire.com/media/ODk1MjU3OWItMTk3Zi00NDRlLThlMmItMDczNjJiMDljZmZiLTExMDM1NTA=/tiny/Krystal-Biotech-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68/small/krys-logo-no-background-with-registered-symbol-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68)\n\nSource: Krystal Biotech, Inc.\n"
        },
        {
          "title": "Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference",
          "url": "https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-present-guggenheim-securities-healthcare",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Krystal Biotech, Inc.](/sites/g/files/knoqqb89436/themes/site/nir_pid1356/dist/images/KRYS-logo-black.svg) ](https://www.krystalbio.com/)\n\n# Investors \n\nInvestor Relations \n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News Releases](/news-releases)\n  * [Events](/events-and-presentations/events)\n  * [Stock Information](/stock-information/stock-quote-chart)\n  * [SEC Filings](/financial-information/sec-filings)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n  * [Scientific Publications](/select-scientific-publications)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Investor FAQs](/shareholder-services/investor-faqs)\n\n\n\n## \n\nKrystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference\n\nNovember 6, 2024 \n\n[Download PDF](/node/10396/pdf)\n\nPITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc](https://www.krystalbio.com/). (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.\n\nA webcast of the presentation will be available [here](https://wsw.com/webcast/guggen/krys/1982821) beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company’s [website](https://ir.krystalbio.com/events-and-presentations/events).\n\n**About Krystal Biotech, Inc.**\n\nKrystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit [http://www.krystalbio.com](http://www.krystalbio.com/), and follow @KrystalBiotech on [LinkedIn](https://www.linkedin.com/company/krystal-biotech-inc/) and [X](https://twitter.com/KrystalBiotech) (formerly Twitter).\n\n**CONTACT****Investors and Media:** Stéphane PaquetteKrystal Biotechspaquette@krystalbio.com\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2Nzk4MiM2NTY2NzEwIzIwOTE5Nzk=)![](https://ml.globenewswire.com/media/OTk5NzI0ZjgtZDgyMy00ZDI3LWExOTItYzhiZTIwZGMwZTNmLTExMDM1NTA=/tiny/Krystal-Biotech-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68/small/krys-logo-no-background-with-registered-symbol-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/ab5ad5d1-5efb-4c72-9ddb-0029600dbb68)\n\nSource: Krystal Biotech, Inc.\n"
        }
      ]
    },
    {
      "section_name": "Corporate Presentation",
      "links": [
        {
          "title": "Corporate Presentation – August 2024",
          "url": "https://ir.krystalbio.com/static-files/d3e52bc6-b3ba-4f0c-a660-5bffa81bf756",
          "content": "\n"
        }
      ]
    }
  ]
}